2021
On August 30, MicroPort CardioFlow's second generation TAVI product VitaFlow Liberty™ and Angelguide® preshaped super stiff guidewire was approved by the NMPA
2021
On 4 February, MicroPort CardioFlow was listed on the Main Board of the Stock Exchange of Hong Kong Limited
2020
2020 Pre-IPO Investment
Obtained marketing approval for VitaFlow® from the National Administration of Drugs, Foods and Medical Devices of Argentina
2019
Our Company was incorporated in the Cayman Islands
Obtained marketing approval for VitaFlow® from NMPA and completed the first VitaFlow® implantation for commercialization
2019 Pre-IPO Investment
2018
Completed the NMPA submission for VitaFlow® for review
Completed first retrievable VitaFlow Liberty™ implantation for Registration Clinical Trial in China
VitaFlow Liberty™ was admitted into the Green Path for Innovative Medical Device by NMPA
Commenced the clinical trial for VitaFlow Liberty™ in Europe for CE Mark
Invested in ValCare and 4C Medical
2017
Commenced the Registration Clinical Trial for VitaFlow Liberty™ in China
Met the primary endpoints of the clinical study of VitaFlow® in China
2017 Pre-IPO Investment
2016
Completed the pivotal clinical trial enrollment for VitaFlow® in China
VitaFlow® was admitted into the Green Path for Innovative Medical Device by NMPA
2015
Completed first implantation of VitaFlow® for pivotal clinical trial in China
MicroPort CardioFlow was established in Shanghai
Commenced feasibility study for VitaFlow Liberty™
2014
Commenced the pivotal clinical trial for VitaFlow®
2010
Commenced early feasibility study for VitaFlow™